Authors: Rui Zhang Bo Pang Tao Xin Hua Guo Yi Xing Shangchen Xu Bin Feng Bin Liu Qi Pang
Publish Date: 2015/01/31
Volume: 53, Issue: 3, Pages: 1452-1460
Abstract
Glioma the most common type of primary central nervous system cancers was progressive with poor survival MicroRNA as a novel biomarker was suspected to be novel biomarkers for glioma diagnosis and prognosis The study aimed at investigating the diagnostic and predictive value of miR221/222 family for glioma In the first phase we compared plasma miR221/222 family levels between 50 glioma patients and 51 healthy controls by realtime qRTPCR amplification Meanwhile a metaanalysis based on published studies and presents study was performed to explore the diagnostic performance of miR221/222 family in human cancers In the second phase we correlated the miR221/222 family expression level with prognosis of glioma using KaplanMeier survival curves The plasma miR221/222 family levels were found to be significantly upregulated in glioma patients P = 0001 The ROC curve analysis yielded an AUC values of 084 95 confidence interval CI 074–093 for miR221 and 092 95 CI 087–094 for miR222 In the metaanalysis the summary receiver operating characteristic sROC was plotted with an AUC of 082 95 CI 078–085 for miR221/222 family It was also demonstrated that high positive plasma miR221 and miR222 were both correlated with poor survival rate miR221 HR = 213 95 CI 105–431 miR222 HR = 209 95 CI 100–437 This study demonstrated that the detection of the miRNA221/222 family should be considered as a new additional tool to better characterize glioma
Keywords: